RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Phase 3 Trial Confirms Benefits of Pirfenidone for IPF
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 11
SP 11
OP 12
DO 10.1177/155989771411005
UL http://mdc.sagepub.com/content/14/11/11.2.abstract
AB The Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial [ASCEND; King TE et al. N Engl J Med 2014] was a Phase 3, multinational, double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. This trial discusses findings.